EVO756 Phase 2b Trial Fails Primary Endpoint; Development Halted for CSU Indication
EVMN sits 51% above its 52-week low of $13.885 on elevated volume (3.4× avg).
Summary
Evommune announced that its EVO756 drug candidate failed its Phase 2b trial for chronic spontaneous urticaria, leading to the immediate halt of development for this indication.
Key Events · Product Development and Regulatory · EVMN
-
Phase 2b Trial Failure
Evommune's EVO756 drug candidate did not meet its primary endpoint in the Phase 2b trial for moderate-to-severe chronic spontaneous urticaria (CSU).
-
Development Halted for CSU
Based on the trial results, the company plans to cease development of EVO756 specifically for the CSU indication.
-
Prospectus Supplement Filed
This 424B3 filing updates an existing prospectus from April 24, 2026, to incorporate the critical negative news of the trial failure into the offering documents.
Analysis · EVMN · Life Sciences
Evommune's drug candidate EVO756 failed to meet its primary endpoint in a Phase 2b trial for chronic spontaneous urticaria (CSU), leading the company to cease development for this indication. This is a significant setback for the company's pipeline, as a Phase 2b failure for a key asset can materially impact future revenue potential and investor confidence, especially as the company has an active offering where this news is being incorporated.
At the time of this filing, EVMN was trading at $21.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $906.9M. The 52-week trading range was $13.89 to $33.20. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.